Form 4 for ATOS ATOSSA THERAPEUTICS, INC.
Accepted 2026-03-30 00:00:00 ET · period of report 2026-03-26 · accession 0001193125-26-132644 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-03-30 | 2026-03-26 | ATOS | Daniel Mark James | CFO | A - Grant | $0.00 | +63.0K | 63.0K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-03-26 | A | A | 63,000 | $0.00 | 63,000 | D | — | — | (F1) Represents a grant of restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. The RSUs shall vest in three equal annual installments on the first three anniversaries of March 26, 2026. |